期刊文献+

单纯11三体骨髓增生异常综合征的血液学特征与预后

Hematological Characteristics and Prognosis of Myelodysplastic Syndrome with Sole Trisomy 11
下载PDF
导出
摘要 目的探讨单纯11三体骨髓增生异常综合征(MDS)的血液学特征和预后。方法对5例单纯11三体MDS进行回顾性分析。对骨髓涂片行Wright-Gimsa染色观察其形态学改变;应用骨髓细胞短期培养法制备染色体标本,采用R显带技术进行染色体核型分析;随访观察转白率、疗效及生存期。结果238例MDS有5例检出单纯11三体核型异常,发生率为2.1%。5例患者外周血全血细胞减少,骨髓粒、红、巨核多系有明显病态的造血改变。难治性贫血(RA)1例,难治性贫血伴原始细胞增多(RAEB)2例,难治性贫血伴原始细胞增多转化型(RAEB-t)2例。4例患者转化为急性髓细胞白血病(M22例、M51例、M61例),转白率80%,总缓解率50%,中位生存期16个月。结论单纯11三体MDS以RAEB、RAEB-t亚型为主,多系有明显病态的造血改变,转化为急性髓细胞白血病发生率高,预后不良。 Objective To explore the hematological characteristics and prognosis of myelodysplastic syndrome (MDS) with sole trisomy 11. Methods A retrospective study of 5 MDS patients with trisomy 11 defined by the FAB classification was performed. The bone marrow smears stained with Wright-Gimsa were observed under microscope. Chromosome specimens were prepared by short-term culture of bone marrow cells and karyotype. Analyses were carried out using R-banding techniques. The rate of transforming into acute leukaemia, the response to chemotherapy and survival times were analyzed. Results The sole trisomy 11 was found in 5 of 238 MDS cases(2.1%). All cases revealed prominent paneytopenia and trilineage dysplasia were present in hone marrow ceils. 1 of these patients had refractory anemia (RA), 2 had refractory anemia with excess of blasts (RAEB). And 2 had RAEB in transformation(RAEB-t). 4 of 5 cases had transformed into acute myelocytic leukaemia (80%). The complete remission rate was 50% with a median survival of 16 months. Conclusion Multilineage dysplasia features was exhibited in MDS with sole trisomy 11, specific chromosomal abnormality was mainly seen in RAEB and RAEB-t with higher risk of transforming into acute myelocytic leukaemia and poor prognosis.
出处 《临床输血与检验》 CAS 2009年第1期35-37,共3页 Journal of Clinical Transfusion and Laboratory Medicine
关键词 骨髓增生异常综合征 11三体染色体 预后 Myelodysplastic syndrome Trisomy 11 chromosome Prognosis
  • 相关文献

参考文献5

  • 1Collado R,Badia L,Garcia S,et al. Chromosome 11 abnormalities in myelodysplastic syndrome [J]. Cancer Genet Cytogenet, 1999,114(1) :58-61.
  • 2Mitelman F,editor. ISCN 1995: an international system for human cytogenetic nomenclature [M]. Basel: Karger S, 1995 : 1-14.
  • 3Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes[J]. Blood, 1997, 89(6) : 2079-2088.
  • 4邱镜滢,赖悦云,柴晔,张艳,师岩,何琦,党辉,陆道培.306例骨髓增生异常综合征染色体核型的研究[J].中国实验血液学杂志,2004,12(4):455-459. 被引量:32
  • 5Bernaconi P,Klersy C,Boni M ,et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes [J]. Br J Haematol, 2007,137 (3) : 193-205.

二级参考文献3

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部